These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 116415)

  • 1. The gangliosidoses: comparative features and research applications.
    Baker HJ; Reynolds GD; Walkley SU; Cox NR; Baker GH
    Vet Pathol; 1979 Nov; 16(6):635-49. PubMed ID: 116415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphology of the gangliosidoses.
    Goebel HH
    Neuropediatrics; 1984 Sep; 15 Suppl():97-106. PubMed ID: 6100800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the testis and epididymis in mouse models of human Tay Sachs and Sandhoff diseases and partial determination of accumulated gangliosides.
    Trasler J; Saberi F; Somani IH; Adamali HI; Huang JQ; Fortunato SR; Ritter G; Gu M; Aebersold R; Gravel RA; Hermo L
    Endocrinology; 1998 Jul; 139(7):3280-8. PubMed ID: 9645704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders.
    Ryckman AE; Brockhausen I; Walia JS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal models of human ganglioside storage diseases.
    Baker HJ; Mole JA; Lindsey JR; Creel RM
    Fed Proc; 1976 Apr; 35(5):1193-201. PubMed ID: 816677
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemistry and genetics of gangliosidoses.
    Sandhoff K; Christomanou H
    Hum Genet; 1979; 50(2):107-43. PubMed ID: 116955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology and potential strategies for the treatment of GM2 gangliosidoses.
    Chavany C; Jendoubi M
    Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of lysosomal storage diseases. Pathomorphologic and biochemical possibilities].
    August CH; Holzhausen HJ; Schmidt H; Stiller D; Seidlitz G; Zschiesche M
    Zentralbl Allg Pathol; 1990; 136(5):443-53. PubMed ID: 2122616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
    Kolter T; Sandhoff K
    J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
    Jeyakumar M; Butters TD; Dwek RA; Platt FM
    Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gangliosidoses and the fetal retina.
    Cogan DG; Kuwabara T; Kolodny E; Driscoll S
    Ophthalmology; 1984 May; 91(5):508-12. PubMed ID: 6330639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.
    Cavender C; Mangini L; Van Vleet JL; Corado C; McCullagh E; Gray-Edwards HL; Martin DR; Crawford BE; Lawrence R
    PLoS One; 2020; 15(12):e0243006. PubMed ID: 33259552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.
    Utz JR; Crutcher T; Schneider J; Sorgen P; Whitley CB
    Mol Genet Metab; 2015 Feb; 114(2):274-80. PubMed ID: 25557439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal acid hydrolases in established lymphoblastoid cell lines, transformed by Epstein-Barr virus, from patients with genetic lysosomal storage diseases.
    Minami R; Watanabe Y; Kudoh T; Suzuki M; Oyanagi K; Orii T; Nakao T
    Hum Genet; 1978 Oct; 44(1):79-87. PubMed ID: 213379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis.
    Sandhoff K; Harzer K
    J Neurosci; 2013 Jun; 33(25):10195-208. PubMed ID: 23785136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 18. Ganglioside storage diseases: an updated review.
    O'Brien JS
    Ital J Neurol Sci; 1981 Aug; 2(3):219-26. PubMed ID: 6804413
    [No Abstract]   [Full Text] [Related]  

  • 19. The liver in lipid storage disease: biochemical basis of pathogenesis and clinical features.
    Brady RO; James SP; Barranger JA
    Prog Liver Dis; 1982; 7():331-46. PubMed ID: 6810410
    [No Abstract]   [Full Text] [Related]  

  • 20. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
    Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
    J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.